Cytokine companies Synthekine, Bright Peak each tap crossovers for megarounds

Engineered cytokine companies Synthekine and Bright Peak each raised nine-figure crossover rounds Thursday, setting both companies up as candidates for public offerings in the coming months.

Menlo Park, Calif.-based Synthekine Inc. banked $107.5 million in series B funding from a syndicate led by Deerfield Management and Janus Henderson Investors. Bright Peak Therapeutics Inc., which is based in San Diego and Basel, Switzerland, raised $107 million in its series B round, with RA Capital as the leader...